People with locally advanced head and neck squamous cell carcinoma who received cetuximab and radiotherapy with concurrent chemotherapy had 27% reduced odds of disease progression or death, compared with those who were given cisplatin and radiotherapy, according to a study in the Journal of Clinical Oncology. However, another study in the same journal showed similar progression-free survival among those who received induction carboplatin-based chemotherapy with cetuximab and radiotherapy and those who underwent standard chemoradiotherapy alone.
Intensified head and neck cancer treatments yield varied results
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.